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Objectives. This prospective study assessed the initial hemody- 
namic effects and long-term clinical benefits of dual-chamber 
pacing with a short atrioventricular (AV) delay in patients with 
chronic heart failure who had no traditional indication for 
pacemaker implantation. 
Background. Dual-chamber pacing with a s ort AV delay has 
been proposed as a nonpharmacologic treatment for drug- 
refractory heart failure. Both initial and long-term hemodynamic 
as well as functional benefits have been reported. All previous 
studies have used an AV delay of 100 ms. Despite encouraging 
results, these previous studies have been anecdotal and uncon-
trolled. 
Methods. This double-blind, randomized, crossover trial in-
cluded 12 subjects with chronic congestive heart failure despite 
optimal medical therapy. Patients were required to be in sinus 
rhythm with no evidence of significant bradyarrhythmias. On the 
day after implantation of a dual-chamber pacemaker, invasive 
hemodynamic measurements were made at varying AV delays 
between 100 and 200 ms. Patients were th n randomized to either 
dual-chamber pacing with a 100-ms AV delay or backup mode 
(VVI at 40 beats/rain). After 4 to 6 weeks, crossover to the other 
pacing mode was programmed. 
Results. Hemodynamic measurements on the day after pace- 
maker implantation demonstrated no b nefit of pacing with any 
AV delay compared with intrinsic conduction. At the optimal AV 
interval for each patient, neither cardiac output (4.5 -+ 1.5 vs. 
4.7 -+ 1.6 liters/rain [mean -+ SD]) nor wedge pressure (16 -+ 
10 vs. 17 -+ 8 mm Hg) improved significantly from baseline 
measurements during intrinsic conduction. The long-term pacing 
protocol was completed in nine patients. Ejection fraction was 
16 -+ 6% with dual.chamber (VDD mode) pacing and 18 -+ 4% in 
backup mode (p = NS). o patient had an increase in ejection 
fraction by >5% with VI)D pacing, nor did any patient improve in 
New York Heart Association functional class with shortAV delay 
dual-chamber pacing. Also, there were no significant reductions in 
body weight or diuretic requirements during this pacing period. 
Conclusions. Dual-chamber pacing with a short AV delay does 
not improve hemodynamic nd linical status or ejection fraction 
measured on the day after pacemaker implantation in patients 
with chronic congestive heart failure. Routine use of pacemaker 
therapy with a short AV delay as a primary treatment of heart 
failure in patients without standard arrhythmic indications is 
unwarranted. 
(J Am Coll Cardiol 1995;26:967-73) 
Despite the well-documented b neficial effects of vasodilator 
therapy, severe heart failure remains a major clinical problem 
and therapeutic challenge (1,2). Pacing with short atrioventric- 
ular (AV) delay is one of several nonpharmacologic modalities 
suggested as neffective option for patients with heart failure 
who are refractory to standard medical therapy (3-8). It has 
even been suggested (9) that pacing for hemodynamic reasons 
alone "...may have an important future role" in treating all 
patients with heart failure caused by dilated cardiomyopathy. 
Such optimism is based on several interesting observations. 
The AV delay clearly affects hemodynamic status, with shorter 
AV intervals appearing to be optimal for at least some 
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pacemaker-dependent patients (10-20). In an echocardio- 
graphic study of changes in hemodynamic status with VDD 
pacing, cardiac output was optimal at a mean AV interval of 
144 ms in 24 patients, most with impaired cardiac function 
(15). In that study, for the 17 patients with the lowest baseline 
cardiac index, optimal AV delay averaged 110 ms (13). How- 
ever, further shortening of AV delay to -<60 ms has been 
shown to have adverse ffects (8,20-23). 
Several investigators have reported that long-term pacing 
with an AV interval of 100 ms yields marked improvement in 
functional status and ejection fraction in patients with heart 
failure who had no standard indication for pacing. However, 
each of these positive reports is anecdotal, uncontrolled and 
based on relatively few patients (3-7). There are other easons 
to question the benefit of pacing with a short AV delay 
specifically for treatment of heart failure. In patients with 
severe cardiomyopathy and permanent pacemakers, the clini- 
cal and hemodynamic importance of changes in AV interval is 
controversial (10,12,13,15-25). In addition, studies of patients 
with clinically indicated pacemakers, including those with and 
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without heart failure, indicate hat there is no single, ideal AV 
delay. Optimal pacemaker AV intervals differ depending on 
ventricular function, heart rate, whether at rest or with exer- 
cise, the presence and severity of underlying intraatrial and 
intraventricular conduction abnormalities and whether func- 
tioning in atrial pacing (DVI) or atrial sensing (VDD) mode 
(8,10-34). Hence, the remarkable improvement s en in the 
initial trials of pacemakers implanted for the treatment of 
heart failure might be a result of the altered AV interval but 
could also be accounted for by other factors, such as sponta- 
neous improvement, the "placebo effect," prevention of brady- 
cardia or changes in concomitant medical therapy. 
We therefore undertook a randomized, controlled trialto 
evaluate the short- and long-term effects of pacing with a short 
(100-ms) AV delay in patients with severe, drug-refractory 
heart failure. We evaluated the short-term hemodynamic 
effects of pacing with various AV intervals on the day after 
pacemaker implantation and used a double-blind design to 
study the long-term effects of pacing with a 100-ms AV delay 
on clinical function and ejection fraction. 
Methods 
This prospective, double-blind, randomized study included 
12 patients with severe (New York Heart Association func- 
tional class III or IV) congestive heart failure of at least 6 
months in duration with a left ventricular ejection fraction 
<35%. All patients were receiving clinically optimized oses of 
digoxin, loop diuretic drugs and angiotensin-converting en- 
zyme inhibitors, with a stable medical r g men for at least 1 
week before randomization. There was no history of chrono- 
tropic incompetence, marked sinus bradycardia, atrial fibrilla- 
tion or second- or third-degree h art block, and no patient met 
standard indications for pacemaker implantation. Written in- 
formed consent was obtained from each patient, and the study 
was approved by the University of Maryland Institutional 
Review Board. 
Pacemaker implantation. Dual-chamber pacemaker im- 
plantation was performed using standard techniques. All leads 
and pulse generators were manufactured by Cardiac Pace- 
makers Inc. Under mild sedation and local anesthesia, cut- 
down to the left (n = 11) or right (n = 1) cephalic vein was 
performed, and two bipolar pacing leads were placed after 
venotomy or subclavian vein puncture when necessary. The 
atrial lead (model 4269) was positioned in or near the right 
atrial appendage, and the ventricular lead (model 4261) was 
placed at the right ventricular apex. Adequate implantation 
criteria included atrial intracardiac electrogram amplitude 
>2.0 mV, ventricular electrogram amplitude >10 mV and 
pacing thresholds <1.0 V in each chamber measured with a 
pulse width of 0.5 ms. A dual-chamber pacemaker (model 937 
or 940) was connected to the two leads, and normal pacemaker 
function was documented. The pulse generator was then 
programmed tobackup mode (VVI at 40 beats/min) to avoid 
any effects of AV sequential pacing on subsequent hemody- 
namic measurements. Right heart catheterization was per- 
formed at the time of pacemaker implantation with a balloon- 
tipped catheter (Swan-Ganz) placed in the pulmonary artery 
through a right internal jugular vein introducer. 
Initial hemodynamic assessment. Hemodynamic measure- 
ments were made in all patients the day after pacemaker 
implantation. The patients were allowed to rest overnight to 
dissipate any hemodynamic changes related to the pacemaker 
implantation procedure or intravascular instrumentation. (35) 
The next morning, after all cardioactive medications and food 
were withheld for at least 8 h, the following hemodynamic 
variables were measured repeatedly until hemodynamic stabil- 
ity was achieved: heart rate, mean arterial pressure, pulmonary 
capillary wedge pressure, m an right atrial pressure and car- 
diac output. Cardiac output was measured by thermodilution 
technique, with three or more 10-ml injections of0 to 3°C 5% 
dextrose. To ensure reproducible hemodynamic recordings, 
measurements were not considered baseline until two com- 
plete sets of measurements obtained at least 10 min apart 
demonstrated <15% variation for both cardiac output and 
pulmonary capillary wedge pressure. Before each measure- 
ment, the transducer was leveled to the same point of the 
patient's midchest. 
Initial hemodynamic measurements were made during in- 
trinsic rhythm and after 10 to 15 rain of pacing in VDD mode 
at various AV delays. The delays were 100, 125, 150, 175 and 
200 ms. Intervals were omitted if significant fusion r pace- 
maker inhibition was evident. The order of pacing was varied 
to minimize effects of hemodynamic drift, cumulative effects of 
pacing and fluid infusion for cardiac output determinations on 
the results. 
Long-term pacing. To assess the effects of long-term pac- 
ing, before hospital discharge patients were randomly assigned 
to one of two pacing modes: VDD with a 100-ms AV delay at 
40 beats/min or VVI at 40 beats/min. The latter mode served as 
a control because no pacing should have resulted in this group 
of patients with heart failure without chronotropic ncompe- 
tence. Moreover, VVI pacing at 40 beats/min occurs in both 
modes, so the treatment ofunexpected marked bradycardia s 
the same. After 4 to 6 weeks of pacing, crossover to the 
alternative mode was performed for an additional 4 to 6 weeks. 
The primary end points for comparison were left ventricular 
ejection fraction a d clinical heart failure status. 
Both the patient and the physicians on the heart failure 
service were uninformed ofthe pacing mode. These physicians 
were responsible for assessing clinical status and adjusting 
medications a  necessary. The members of the electrophysiol- 
ogy service maintained the randomization scheme, pro- 
grammed the pacemaker and performed all pacemaker valu- 
ations. The measurements made after each pacing period were 
an assessment of clinical status according to functional class 
and a radionuclide ventriculogram to measure left ventricular 
ejection fraction. 
Three patients did not complete the long-term pacing 
protocol. One patient had trial electromechanical dissociation 
identified by echocardiography before randomization. Al- 
though atrial pacing was not part of the present study, altering 
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Table 1. Basel ine Characterist ics of the 12 Study Patients 
Age (yr) 65 ± 8 
Male gender I(XF;k 
EF (%) 20 + 6 
NYHA class 
II1 83~ 
IV 17eli 
Etiology. 
CAD 67(:~ 
IDCM 33c:; 
Heart rate (beats/min) 85 - 6 
PR interval (ms) 214 ± 45 
QRS complex (ms) 130 + 41 
QT interval (ms) 451 + 48 
Data presented are mean value + SD or percent of patients. EF -- ejection 
fraction: CAD = coronary artery, disease; IDCM = idiopathic dilated cardio- 
myopathy; NYHA = New York Heart Association functional class. 
AV delay should have no hemodynamic effect in the absence of 
atrial systole. This patient underwent cardiac transplantation l 
month after pacemaker implantation. In another patient, 
randomization was delayed because of intercurrent illnesses 
(urinary retention complicated by urosepsis and progression of 
renal insufficiency). He recovered sufficiently to be discharged 
from the hospital, but randomization was again deferred 
pending stabilization of renal function and heart failure; 
however, he died suddenly at home. The third patient had both 
severe heart failure and recurrent syncope with sustained 
ventricular tachycardia readily inducible with programmed 
cardiac stimulation. He underwent placement of an implant- 
able defibrillator as well as a p cemaker. The long-term phase 
of the pacing study was deferred pending recovery from the 
initial effects of operation. He subsequently developed an 
infection that necessitated removal f his implanted evices. 
Statistical analysis. Comparisons of the initial hemody- 
namic measurements at v rious AV delays were made using 
analysis of variance for repeated measures. For comparisons 
between long-term pacing modes, the two-tailed Student t test 
for paired data was used. A p value <0.05 was considered 
significant, and results are shown as mean value _+ SD. 
Results 
Patients. All patients had severe heart failure (functional 
class III or IV) with an ejection fraction <35% and duration of 
symptoms at least 6 months. A summary of the patient cohort 
is shown in Table 1. The mean age of the 12 patients was 65 
years. All patients were male, and 67% had documented 
ischemic heart disease as evidenced by a history of myocardial 
infarction, coronary artery b pass surgery or multivessel coro- 
nary artery disease demonstrated by cardiac catheterization. 
Despite optimization of medical therapy with a combination of
digoxin, angiotensin-converting enzyme inhibitors and diuretic 
drugs in all patients, the severity of heart failure symptoms was 
graded functional class IV in 2 patients and functional class II1 
in the other 10 patients at the start of the study. The mean daily 
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Figure 1. Effect of dual-chamber pacing on cardiac index, shown in 
intrinsic sinus rhythm (Int) and after pacing in VDD mode at 
atrioventricular (AV) delays of 100 to 200 ms. Data shown are mean 
value (circles) and SD (vertical bars). 
dose of furosemide in this group was 171 + 42 rag, and the 
duration of symptoms was 46+ 42 months. 
Noninvasive imaging studies confirmed the diagnosis of 
dilated cardiomyopathy with a left ventricular ejection fraction 
of 20 +_ 6% by radionuclide ventriculography and cardiomeg- 
aly present on chest radiograph. In addition, echocardiography 
revealed moderate or severe mitral regurgitation i 46% of 
patients and moderate or severe tricuspid regurgitation in 
36%. 
A summary of the baseline electrocardiographic (ECG) 
intervals is also presented in Table 1. Prolongation of the PR 
and QT intervals and QRS complex is consistent with e 
diffuse ECG abnormalities observed in patients with severe 
dilated cardiomyopathy. All subjects were in sinus rhythm, as 
required for study entry. First-degree AV block (PR interval 
~>200 ms) was present in 9 of 12 patients, and intraventricular 
conduction delay (QRS complex ->110 ms) was also present in 
9 of 12 patients. Baseline PR interval prolongation ensured 
that short AV delay pacing would result in right ventricular 
pre-excitation without fusion. 
Initial hemodynamic effects of pacing. The initial effects of
AV delay were assessed in all p tients after pacemaker im- 
plantation. There was no effect of pacing on any hemodynamic 
variable measured over the range of AV delays studied. The 
effect of AV interval during pacing on cardiac index is shown 
in Figure 1. Overall there was no significant effect of AV delay 
on this variable, with only minimal group changes noted and no 
consistent optimal AV delay. 
The AV interval also had no significant effect onpulmonary 
capillary wedge pressure (Fig. 2). Contrary to the anticipated 
trend toward improved hemodynamic status with a short 
(100 ms) AV delay, there appeared to be a small increase in 
wedge pressure compared with measurements in intrinsic 
rhythm that did not reach statistical significance. 
Varying the AV interval also resulted in no significant 
effects on heart rate or mean arterial, pulmonary or right atrial 
pressures (Table 2). One possibility for the lack of group 
hemodynamic benefit at any AV delay is that the optimal AV 
interval varied from patient o patient. To assess this possibil- 
ity, the optimal AV delay for each patient was defined as the 
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Figure 2. Effect of dual-chamber pacing on pulmonary capillary wedge 
pressure (PCWP), shown in intrinsic sinus rhythm (lnt) a d after 
pacing in VDD mode at atrioventricular (AV) delays of 100 to 200 ms. 
Data shown are mean value (circles) and SD (vertical bars). 
interval that resulted in the greatest cardiac output. For each 
hemodynamic variable, measurements a  the optimal AV delay 
were compared with those made during intrinsic rhythm. 
Despite this procedure, which maximizes any possible benefi- 
cial effect of pacing, no significant hemodynamic effect of 
pacing could be demonstrated. Cardiac output increased 
nonsignificantly from 4.5 + 1.5 to 4.7 _+ 1.6 liters/rain, and 
wedge pressure increased slightly from 16 + 10 to 17 _+ 
8 mm Hg. Thus, neither pacing with a 100-ms AV delay nor 
with a selected optimal AV interval significantly improved 
hemodynamic measurements compared with intrinsic sinus 
rhythm. 
Long-term pacing. Nine patients completed the double- 
blind, randomized protocol with 4 to 6 weeks of pacing in VDD 
mode with a 100-ms AV delay and a similar duration of pacing 
in VVI mode at 40 beats/rain. The VVI pacing served as a 
control because no pacing was expected or observed in this 
programmed mode in these patients with heart failure, a 
relatively high rest heart rate and no evidence of chronotropic 
incompetence, bradycardia or heart block. Pacemaker valua- 
tions by the electrophysiology physicians demonstrated normal 
pacemaker activity in all patients with no evidence of atrial 
sensing problems or ventricular exit block. 
The primary, end points for evaluation were the left ven- 
tricular ejection fraction and heart failure status. Ejection 
fractions at each of the two pacing modes are shown in Figure 
Table 2. Effect of Atrioventricular Delay on 
Hemodynamic Variables 
HR MAP RA PA 
AV delay (beats/rain) (mm Hg) (mm Hg) (mm Hg) 
Intrinsic SR 85 _+ 6 86 ~ 8 8 ± 8 30 2 8 
100 ms 84 _+ 8 85 z 8 8_+ 8 32 2 9 
125 ms 81 -+ 8 84 :: 8 8 ~" 9 31 ± 9 
150 ms 83±7 85~11 5=5 32*-10 
175ms 81-8  82 ~ -11 9_ '8 26=6 
200 ms 80_+9 83_+ 11 8±6 3024 
Data presented are mean value ~ SD. AV = atrioventricular; HR = heart 
rate; MAP = mean systemic arterial pressure; PA = pulmona~ artery, pressure: 
RA = right atrial pressure; SR = sinus rhythm. 
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Figure 3. Effect of pacing on left ventricular ejection fraction as 
measured by radionuclide ventriculography after 4 to 6 weeks of 
dual-chamber pacing in VDD mode (100-ms atrioventrieular delay) 
and after a similar period in backup mode (VVI). Circles = individual 
patient data. 
3. Of note, ejection fraction data from one patient were 
excluded because during the VDD phase he developed atrial 
fibrillation complicated by worsening heart failure. There was 
no significant improvement in ejection fraction with short AV 
delay pacing because the mean ejection fraction was 18 _+ 4% 
in VVI mode and 16 _+ 6% in VDD mode. Moreover, no 
patient had an improvement of ->5% with VDD pacing 
compared with VVI control pacing. 
Heart failure status (functional class) was assessed with 
each pacing mode. Physicians making this assessment were 
unaware of the programmed pacemaker settings. No patient 
showed an improvement i  functional class with VDD pacing 
compared with VVI pacing. All patients had class III heart 
failure after VVI pacing, and one patient had class IV heart 
failure after VDD pacing. Corroborating the lack of functional 
improvement, there was no significant change in body weight, 
heart rate or blood pressure with VDD pacing (Table 3). 
Moreover, the diuretic requirements of the patients were also 
unchanged. 
Discuss ion  
To our knowledge, the present study is the first prospective, 
randomized study of pacemaker therapy in patients with severe 
congestive heart failure. In these patients with no standard 
clinical indication for a pacemaker, we assessed initial hemo- 
Table 3. Effect of Long-Term Pacing on Clinical Measurements 
Pacing Mode 
VVI VDD 
(mean _+ SD) (mean ± SD) 
Weight (kg) 74 ± 5 75 _+ 5 
SBP (mm Hg) 116 -+ 6 113 _+ 6 
DBP (mm Hg) 71 -+ 4 76 ± 6 
Heart rate (beats/min) 80 -+ 3 84 ± 3 
Furosemide (rag/day) 171 -+ 31 163 ± 29 
DBP = diastolic blood pressure: SBP = systolic blood pressure. 
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dynamic hanges, comparing intrinsic rhythm with pacing at 
varying AV intervals, and then observed the long-term re- 
sponse during 4 to 6 weeks of pacing using a short (100 ms) AV 
delay compared with 4 to 6 weeks of intrinsic rhythm (pace- 
maker programmed tostandby VVI mode). Neither the initial 
nor long-term measurements identified any benefit of dual- 
chamber pacing in these advanced patients with heart failure. 
The absence of clinical improvement or increase in ejection 
fraction is supported by the lack of any weight loss or reduction 
of diuretic drug dose during the period of pacing. 
The need for additional innovative therapeutic options in 
the increasingly large group of patients with chronic symptom- 
atic congestive heart failure is obvious (1,2). Donor availability 
limits cardiac transplantation to only a minority of patients 
with medically refractory heart failure (36). Dynamic cardio- 
myoplasty, although reported to have promising initial results, 
may also be limited in applicability because of its surgical 
morbidity, cost and lack of controlled observations (37). Com- 
pared with these other nonpharmacologic approaches, the 
appeal of pacemaker therapy is its relative ease and safety as 
well as ready availability, even for patients with the most 
advanced heart failure. Pacemaker implantation can be per- 
formed under local anesthesia with minimal morbidity and 
recuperation time. Moreover, the technology is well estab- 
lished, available and less expensive than transplantation or 
cardiomyoplasty. 
Long-term pacing. Previous studies (3-7) of pacing with 
short AV intervals in patients with heart failure reported 
consistent, marked benefits. In the largest series to date, 
Hochleitner et al. (3,4) reported a striking lessening of symp- 
toms and improvement in ejection fraction in 16 patients with 
dilated cardiomyopathy. In marked contrast o our findings, 
they claimed a 10% improvement in mean ejection fraction. 
This benefit appeared to persist for at least several years (4). 
More recently, it has been reported (7) that a similar improve- 
ment can be observed with dual-chamber pacing in patients 
with ischemic heart disease. In all of these studies, an AV delay 
of 100 ms was used, which was chosen either a bitrarily or with 
serial hemodynamic measurements. Hemodynamic studies 
(8,18,19,38,39) suggest tha the possible mechanism of benefit 
of short AV delay pacing may be optimization of ventricular 
filling or reduction of diastolic mitral regurgitation. However, 
AV sequential pacing with a short AV interval results in a 
pattern of abnormal ventricular activation with right ventricu- 
lar pre-excitation because these patients tend to have diffuse 
conduction system disease, including PR interval prolongation. 
Although the importance of activation sequence has been 
debated, such abnormal activation may adversely affect both 
systolic and diastolic function and hence offset some of the 
benefit of optimizing ventricular filling (40-43). 
Our controlled observations during long-term pacing 
yielded a disappointing outcome in patients with advanced 
heart failure. The striking discrepancy between these findings 
and earlier uncontrolled reports that suggested consistent 
beneficial effects from short AV delay pacing highlights the 
critical importance of performing controlled trials before new 
technologies become widely applied. 
The inability of the present prospective randomized study 
to replicate previous findings suggests that factors other than 
short AV delay pacing contributed to the favorable outcomes 
previously described. Such factors might include spontaneous 
improvement of heart failure (44), a "placebo" effect of 
performing an intervention on chronically ill patients, investi- 
gator bias in subjective classification of symptoms, other 
changes in unblinded treatment modalities or a beneficial 
effect of pacing for unsuspected bradycardia or heart block. In 
the series reported by Hochleitner et al. (3,4), several patients 
had inappropriate rest bradycardia that improved after short 
AV delay pacing. More important, nearly 50% of the cohort 
had been receiving sustained obutamine or dopamine infu- 
sions that were withdrawn after pacemaker insertion (3,4). The 
improvement in these patients could reflect recovery from the 
adverse ffects of prolonged inotrope therapy (45). Perhaps 
the modest hemodynamic benefit of short AV delay pacing was 
relevant only because it led to recovery from excess bradycar- 
dia or permitted withdrawal of agents that had been contrib- 
uting to progressive deterioration. 
Initial hemodynamic response to pacing. Two recent stud- 
ies (8,25) examined the initial hemodynamic response to 
variable AV interval pacing in patients with heart failure, with 
no net hemodynamic mprovement observed. However, on 
retrospective analysis Nishimura et al. (8) found a subgroup 
with increased baseline PR interval that had a significant 
increase in cardiac output. This apparent increase in cardiac 
output was seen in only five of their eight patients with 
first-degree AV block and could be identified only by selecting 
the optimal AV delay for each patient. Furthermore, the 
optimal AV delay was quite variable, and the clinical relevance 
of comparing baseline data with retrospectively determined 
optimal data is uncertain. In contrast to their data, we were 
unable to detect any clinically important hemodynamic re- 
sponse, even when performing a similar analysis. In our 
patients with baseline PR interval >200 ms (mean 242 _+ 
42 ms, range 210 to 320), pulmonary capillary wedge pressure 
remained unchanged, and cardiac index increased only mini- 
mally (from 2.3 _+ 1.0 to 2.5 +_ 1.0 liters/min per m 2) when 
baseline and optimal data were compared. 
Study limitations. There are certain limitations to our 
study that need to be addressed. Initial hemodynamic assess- 
ment included measurements of cardiac output by thermodi- 
lution. Although this technique may slightly underestimate 
cardiac output in patients with tricuspid regurgitation and 
congestive heart failure (46), it is reproducible and useful for 
serial comparisons as used in the present s udy (46,47). 
The standard AV interval of 100 ms was the only delay 
chosen for the long-term phase of the protocol. It is possible 
that a benefit may have been observed with pacing with a 
different fixed AV delay or if the delay was elected individu- 
ally on the basis of initial hemodynamic measurements. How- 
ever, all previous studies that reported clinical benefit in 
patients with heart failure used an AV delay of 100 ms, so this 
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value was chosen in the present study to maintain consistent 
methodology. In addition, short-term pacing failed to identify, 
any AV interval between 100 and 200 ms that improved 
hemodynamic function, and AV delays <70 ms have previously 
been reported (8,20-24) to worsen hemodynamic status in 
animal models and in patients with heart failure. Another 
limitation of the present study is that long-term pacing in each 
mode was performed for only 4 to 6 weeks. It is possible that 
a longer duration of pacing might have resulted in eventual 
lessening of heart failure. This duration of pacing was chosen 
because previous studies have reported a clinical benefit with 
pacing for <1 month (3-7). Although this aspect is uncon- 
trolled, our patients who completed the randomized trial were 
then programmed to short AV delay pacing, but no marked 
clinical improvements were noted, even with much longer 
durations of pacing. 
A final limitation of the present study is the number of 
subjects enrolled. Initially, 12 patients were recruited, but only 
9 completed the long-term pacing protocol. Such attrition is 
expected in the investigation of these chronically ill patients 
with advanced heart failure. The present study had 80% power 
to show a 35% increase in cardiac output with pacing. Simi- 
larly, there was an 80% power to show a 27% increase in 
ejection fraction with VDD pacing compared with backup 
mode. However, both cardiac output and ejection fraction 
decreased slightly with short AV delay pacing. Although a 
small cohort raises the possibility that a small but statistically 
significant improvement was missed, it is very unlikely that 
clinically important improvement in heart failure would result 
from short AV delay pacing in patients with severe, chronic 
heart failure comparable to our study cohort. Such an improve- 
ment would be necessary to advocate the routine implantation 
of dual-chamber pacemakers in these patients. The lack of 
benefit was reinforced by the observation that no single 
individual evidenced clearly definable symptom lessening or a  
increase in ejection fraction of at least 5%. Perhaps patients 
with a high filling pressure are least likely to benefit from 
modifying the AV interval (26). Whether larger studies would 
identify a selected cohort, particularly patients with less ad- 
vanced disease and different baseline characteristics (including 
marked first-degree AV block), who might still benefit from 
pacing is uncertain. This issue can only be addressed in future 
controlled studies, including the evaluation of dual-chamber 
pacing at higher rates or alternative pacing techniques, such as 
right ventricular septal or biventricular pacing (48) that might 
yield more "physiologic" ventricular activation and hence 
might be of greater benefit for patients with heart failure. 
Summary. To our knowledge, the present study is the first 
randomized, double-blind trial of short AV delay pacing for 
the treatment of chronic congestive heart failure in a group of 
patients with no documented standard indication for pace- 
maker implantation. Despite previous promising anecdotal 
reports of hemodynamic and clinical benefit with this nonphar- 
macologic modality, no improvement in hemodynamic status 
shortly after pacemaker implantation or i  clinical status and 
ejection fraction after long-term pacing were noted. These 
results indicate that the routine use of pacemaker therapy as a 
primary treatment of congestive heart failure in patients 
without standard arrhythmic indications is unwarranted. 
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